MedTrace Logo

Production of iPSC Derived RPE Cells for Transplantation in AMD

NCT02464956 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2022-04-12

No results posted yet for this study

Summary

No treatments exist for Age-related Macular Degeneration (AMD) when there is cell loss such as in late wet AMD or dry AMD. The differentiation of RPE cells from patient derived iPSC will offer valuable source of tissue for transplantation in these forms of AMD and may form basis for a future treatment option in terms of cell transplantation.

Conditions

  • Age Related Macular Degeneration (AMD)

Sponsors & Collaborators

Eligibility

Min Age
50 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-08-31
Completion
2019-02-28

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02464956 on ClinicalTrials.gov